Imovax POLIO, vaccination with Imovax POLIO in Odintsovo and Golitsyno, price

Prices

Our doctors

How to get there

Poliomyelitis is an infectious pathology that occurs in an acute form. It can affect children and adults. This disease is caused by different types of polio virus. There are non-paralytic and paralytic forms of pathology.

The latter type is recognized by doctors as the most dangerous, capable of causing permanent paralysis and death. For the purpose of protection, vaccinations begin from an early age. Various vaccinations are used for prevention. The drug Imovax Polio has good reviews.

Make an appointment

Please check the cost of services with the clinic’s medical consultants by phone

Service	Price
Imovax POLIO	1500 rub.

Imovax Polio: application features

The drug is quite a powerful drug that can cause complications if improperly vaccinated. Instructions for use of Imovax Polio are contained in each package with the composition of the drug. When carrying out vaccination, it is imperative to familiarize yourself with the description and features of use. The main factors to pay attention to in the instructions are:

Purpose of the drug. Its main purpose is to enable the human body to develop immunity to a disease such as polio.
Vaccination is carried out exclusively in two ways: subcutaneously or intramuscularly.
Before vaccinating a patient, he must be examined by a doctor. The vaccine is administered only after the doctor's permission.
After the first vaccination, it is mandatory to observe the frequency of vaccination, and this is monitored in medical facilities at the place of residence.

Children are vaccinated against polio before they are three months old. It is during these three months that the child is protected from illness by the mother’s immunity through breastfeeding. The first vaccination of children begins at three months of age. The dosage and frequency of vaccination is carried out according to the following scheme:

A dosage of 0.5 ml of the drug is administered to children aged three, four and 6 months. Often the interval between vaccinations is about 1.5 months, which is the ideal vaccination schedule.
The next vaccination is carried out at the age of one year. The dosage remains standard - 0.5 ml.
The next vaccination is given at 18 months, maintaining the same dosage.
In the future, the Imovax Polio vaccine, as the instructions suggest, is administered in the same dosage every five years of a person’s life.
When a child becomes an adult, that is, from the age of 18, vaccination is carried out every 10 years.

Imovax Polio

Imovax Polio. Vaccine for the prevention of polio, inactivated. Description Imovax Polio is a clear, colorless liquid. Purpose The Imovax Polio vaccine is intended for the prevention of polio, incl. in persons for whom vaccination against polio using live attenuated polio vaccine (oral polio vaccine - OPV) is contraindicated. Contraindications Imovax Polio is not used against the background of diseases accompanied by fever, acute manifestations of an infectious disease or exacerbation of a chronic disease. In these cases, vaccination with the Imovax-Polio vaccine should be postponed until recovery. Hypersensitivity to streptomycin, neomycin and polymyxin B, as well as to the components included in the Imovax Polio vaccine. Use during pregnancy: There is insufficient data on the use of Imovax Polio during pregnancy.

The Imovax Polio vaccination during pregnancy can only be used for epidemic indications.

Directions for use and doses

The Imovax-Polio vaccine is administered intramuscularly or subcutaneously in a dose of 0.5 ml. The Imovax Polio vaccination course consists of 3 injections of one dose of vaccine (0.5 ml) with an interval of at least 1 month. The first revaccination of Imovax Polio is carried out 1 year after the third administration of the vaccine. Subsequent Imovax Polio revaccination is carried out every 5 years until the patient reaches the age of 18 years and then every 10 years. In accordance with the National Calendar of Preventive Vaccinations of the Russian Federation, the polio vaccination course consists of 3 injections of the drug with an interval of 1.5 months, at the ages of 3, 4.5 and 6 months, respectively. For children whose immunization with Imovax Polio for any reason was limited to one or two vaccinations, subsequent vaccinations against polio can be carried out with a live attenuated vaccine (OPV vaccination) within the time frame determined by the National Preventive Vaccination Calendar.

Use simultaneously with other medications

Imovax Polio can be used simultaneously (on the same day) with other vaccines (with the exception of the BCG vaccine - in accordance with the National Calendar of Preventive Vaccinations of the Russian Federation), provided that they are administered to different parts of the body using different syringes.

Adverse reactions

The frequency of all adverse reactions recorded during the practical use of the Imovax Polio vaccine is very small, amounting to less than 0.01% of the total number of vaccine administrations. The most commonly observed local reactions to the Imovax Polio vaccine (swelling, soreness, redness and hardness at the injection site, these reactions can occur within 48 hours after administration and last up to 2 days) and a short-term increase in body temperature within 48 hours after administration, about 20% and 10% respectively for all reported cases of adverse reactions. After vaccination with Imovax Polio, the following common adverse reactions are observed:

on the part of the hematopoietic organs and lymphatic system, enlargement of lymph nodes;
on the part of the immune system, hypersensitivity reactions to vaccine components such as allergic reactions (rash, urticaria), anaphylactic reactions and anaphylactic shock;
from the musculoskeletal system, muscle and joint soreness for several days after administration;
from the nervous system: excitement, drowsiness, irritability; short-term convulsions, convulsions caused by increased body temperature; headache; short-term and medium-duration paresthesia (mainly limbs), within 2 weeks after administration.

Release form

The Imovax Polio vaccination is available in 1-dose syringes, 1 syringe per package; or in ampoules of 1 dose, 20 ampoules per package

Contraindications

The only and main indication for the use of the drug “Imovax Polio” is the prevention of poliomyelitis.

There are some contraindications to vaccination with this drug that you should be aware of:

in the presence of acute infectious ailments;
Vaccination is not given at the age of less than 3 months;
if you have an allergic reaction to one of the components of the vaccine. In this case, on an individual basis, the doctor prescribes vaccination of the patient against polio using other drugs, for example, Poliorix.

Imovax Polio® (vaccine for the prevention of polio, inactivated) (Imovax Polio)

Adverse events are listed according to systemic organ class and frequency of occurrence. The frequency was determined based on the following criteria: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10000 to < 1/1(00), very rare <1/10000), frequency unknown (cannot be estimated from available data).

Clinical trial data

Local and general reactions

Very common: pain at the injection site, fever after vaccination with the 1st and 2nd dose;

Often: erythema at the injection site, fever after revaccination with the 3rd dose;

Uncommon: swelling at the injection site.

From very often to often: an increase in body temperature up to 38.5-39.5 ° C, transient within 24-48 hours after vaccination/re-vaccination with the drug Imovax Polio®.

Post-marketing surveillance data

Since reports of adverse events during commercial use of the drug were received very rarely and from a population with an unknown number of patients, their frequency was classified as “frequency unknown.”

The safety profile of Imovax Polio® vaccine does not differ significantly between patients of different ages, given the relative frequency of adverse events and the fact that some events are age specific (for example, seizures in infants and children from 2 to 11 years of age, myalgia/arthralgia in adolescents and adults). In addition, due to the simultaneous administration of other vaccines with the Imovax Polio® vaccine, a precise cause-and-effect relationship between the occurrence of adverse events and the use of the vaccine cannot be established.

The most common adverse events: local reactions and increased body temperature (approximately 20% and 10% of all registered adverse events, respectively).

Local and general reactions

Swelling, pain, redness at the injection site, appearing in the first 48 hours after injection and lasting 1-2 days; fever in the first 24-48 hours after vaccination.

From the central nervous system

Excitement, drowsiness, irritability in the first hours or days after vaccination (short-term).

From the nervous system

Brief convulsions, febrile convulsions in the first few days after vaccination; headache; transient mild paresthesia (mainly in the extremities) in the first 2 weeks after vaccination.

In very rare cases, seizures may occur later than the specified time. However, after 7 days there is no evidence linking seizures to vaccination.

Inactivated polio vaccine “Imovax Polio”

Sanofi Pasteur, France

Release form: 1 syringe / 1 dose / 0.5 ml.

Vaccination schedule: three times (3 months – 4.5 months – 6 months). Revaccination after 1 year, subsequent boosters every five years until age 18 and then every 10 years.

INSTRUCTIONS FOR USE of the vaccine for the prevention of poliomelitis inactivated Imovax Polio.

Latin name: Imovax Polio / Imovax Polio. Composition and release form: Imovax Polio injection solution for intramuscular and subcutaneous administration in syringes or ampoules, 1 dose of 1, 10 and 20 pcs. packaged. 1 dose of vaccine (0.5 ml) Imovax Polio contains: inactivated vaccines for the prevention of poliomyelitis caused by poliovirus type 1, type 2 and type 3; 1 vaccine dose (corresponds to the amount of antigen that meets the standards and requirements of the antigenic activity test described in the French and European pharmacopoeias); 2-phenoxyethanol, formaldehyde. Properties/Action: Imovax Polio is an inactivated vaccine for the prevention of polio. The Imovax Polio vaccine is produced from polio viruses of 3 types, cultivated on the VERO cell line and inactivated with formaldehyde. The Imovax Polio vaccine forms specific immunity against the polio virus. Immunity is acquired after the 3rd injection of the Imovax Polio vaccine, strengthens with subsequent administrations of the drug and persists for at least 5 years after the first revaccination. After administration of 3 doses of the Imovax Polio vaccine, seroconversion is observed in 95-100% of vaccinated people. The Imovax Polio vaccine causes the production of a significant amount of virus-neutralizing antibodies (starting from the second injection), regardless of the general condition of the vaccinated (immunodeficiency, intestinal pathology, dystrophy). Indications: Imovax Polio vaccine is used for the prevention of polio, including in persons with contraindications to the use of “live polio vaccine”; It is possible to use the Imovax Polio vaccine in pregnant women. Method of administration and doses: The regimen for using the Imovax Polio vaccine is determined by the National Preventive Vaccination Calendars. The Imovax Polio vaccine is prescribed in the form of subcutaneous and intramuscular injections. The recommended age for starting vaccination with Imovax Polio is 3 months. Primary vaccination with Imovax Polio: 3 injections (at least 2 injections) of 0.5 ml with a minimum interval of 1 month between them. Revaccination with Imovax Polio: 1 year after the last injection, then every 5-10 years. The used syringe must be destroyed. Contraindications: - acute infectious diseases accompanied by an increase in body temperature (you should wait until you have recovered for vaccination); - hypersensitivity to streptomycin; - early childhood (up to 3 months). Side effects: In rare cases, when using the Imovax Polio vaccine, erythema at the injection site may appear, as well as a slight increase in body temperature. All cases of unusual vaccination reactions should be reported to the doctor or pharmacist, the National Authorities for the Control of Medical Immunobiological Products and the Pasteur Merrier Connaught Representative Office. Drug interactions: Imovax Polio vaccine can be used in combination with other injectable forms of vaccines: for the prevention of diphtheria, tetanus, whooping cough, infections caused by Haemophilus influenzae type b, and hepatitis B. Storage conditions: At temperatures from + 2°C to + 8 °C. Do not freeze. Shelf life: 36 months. Dispensing conditions from pharmacies are by prescription.

← Back